EBS financials
Emergent BioSolutions (EBS) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
EBS income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $742.90M | $350.60M | $110.20M | $52.60M | 0.93 |
| 2024 | $1.04B | $375.40M | -$108.70M | -$190.60M | -3.60 |
| 2023 | $1.05B | $360.00M | -$726.40M | -$760.50M | -14.85 |
| 2022 | $1.12B | $473.00M | -$170.00M | -$211.60M | -4.22 |
| 2021 | $1.77B | $793.20M | $341.40M | $219.50M | 4.06 |
| 2020 | $1.58B | $863.10M | $438.50M | $305.80M | 5.67 |
- EBS revenue was $742.90M in fiscal 2025, net income $52.60M.
Updated 2026-11-03 23:15 UTC